10-Q: Akoya Biosciences Reports Second Quarter 2024 Results: Revenue Declines Amid Cost-Cutting Measures

Akoya Biosciences experienced a decrease in revenue and a net loss for the second quarter of 2024, while implementing cost-saving initiatives including a workforce reduction and facility consolidation.

Summary

• Akoya Biosciences reported a total revenue of $23.2 million for the three months ended June 30, 2024, a slight decrease from $23.5 million in the same period of 2023.
• Product revenue decreased by 7% to $15.9 million, primarily due to lower instrument sales, while service and other revenue increased by 14% to $7.2 million.
• The company's net loss for the quarter was $13.1 million, compared to a net loss of $20.8 million in the second quarter of 2023.
• For the six months ended June 30, 2024, total revenue was $41.5 million, down from $44.9 million in the same period of 2023.
• The net loss for the first six months of 2024 was $36.6 million, compared to $39.6 million for the same period in 2023.
• The company implemented a workforce reduction in January 2024, resulting in restructuring charges of $1.4 million for the six months ended June 30, 2024.
• Akoya also recorded an impairment charge of $3.0 million related to exiting its Menlo Park, California facility.
• As of June 30, 2024, Akoya had $48.7 million in cash, cash equivalents, and marketable securities.
• The company placed 51 instruments in the second quarter of 2024, compared to 72 in the same period of 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive developments like reduced losses and increased service revenue, but these are overshadowed by declining overall revenue, reduced instrument placements, and significant restructuring and impairment charges. The company is taking steps to improve its financial position, but the overall sentiment is cautious due to the current financial performance.

Positives

• The net loss decreased in both the second quarter and the first six months of 2024 compared to the same periods in 2023.
• Service and other revenue increased by 14% in the second quarter of 2024.
• Recurring revenue as a percentage of total revenue increased to 44% for the three months ended June 30, 2024, and 48% for the six months ended June 30, 2024.
• The company implemented cost-saving measures, including a workforce reduction and facility consolidation.

Negatives

• Total revenue decreased slightly in the second quarter of 2024 and decreased by 8% for the first six months of 2024.
• Product revenue decreased by 7% in the second quarter of 2024.
• Instrument placements decreased from 72 in Q2 2023 to 51 in Q2 2024.
• The company incurred a net loss of $13.1 million in the second quarter of 2024 and $36.6 million for the first six months of 2024.
• The company recorded a $3.0 million impairment charge related to exiting its Menlo Park facility.

Risks

• The company's future success depends on its ability to commercialize products, launch new products, and obtain additional capital.
• Akoya is subject to risks including market acceptance of its products, competition, protection of proprietary technology, and raising additional capital.
• The company has incurred losses since its inception and expects to continue to incur operating losses for the foreseeable future.
• Fluctuations in instrument sales can significantly impact revenue from period to period.
• The company relies on third-party contract manufacturers and single-source suppliers, which could pose supply chain risks.
• The company's debt agreement includes financial covenants that could limit its operational flexibility.

Future Outlook

The company expects to continue to incur operating losses for the foreseeable future but plans to improve results of operations in an effort to achieve cash flow positivity. They believe their existing cash, cash equivalents, marketable securities, and anticipated cash flows from operations will be sufficient to meet their working capital and capital expenditure needs for at least the next 12 months.

Management Comments

• Management is focused on increasing sales of their PhenoCycler and PhenoImager platforms.
• Management believes that expansion of the installed base will drive an increase in recurring reagent and instrument service revenue.
• Management aims to mitigate downward pressure on average selling prices by increasing the value proposition of their instruments and consumables.

Industry Context

The spatial biology market is rapidly evolving, and Akoya is positioned as a key player with its end-to-end solutions. The company's focus on both discovery and clinical applications aligns with the growing demand for spatial phenotyping technologies in research and diagnostics. The company is competing with other companies in the life sciences technology space, and the results reflect the challenges of commercializing new technologies in a competitive market.

Comparison to Industry Standards

• Akoya's revenue decline in instrument sales contrasts with some other life science companies that have seen growth in instrument placements, suggesting a need for Akoya to improve its sales strategy or product positioning.
• The company's gross margin of 52% for the six months ended June 30, 2024, is within the range of other life science companies, but there is room for improvement through better cost management and pricing strategies.
• The company's recurring revenue of 48% for the six months ended June 30, 2024, is a positive sign, but it needs to continue to grow to provide a more stable revenue base.
• Compared to companies like NanoString Technologies and 10x Genomics, Akoya is still in a growth phase and is working to establish a strong market position.
• The company's focus on both research and clinical applications is similar to other companies in the spatial biology space, but Akoya's ability to deliver a menu of clinical IVD tests on its platform is a potential differentiator.

Corporate Governance

Related Party Transactions

• The company incurred costs of goods sold of approximately $3.1 million and $3.8 million for the six months ended June 30, 2024 and 2023, respectively, related to sales of consumables manufactured by Argonaut Manufacturing Services Inc., a related party.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and net losses, but encouraged by the cost-cutting measures and potential for future growth.
• Employees have been impacted by the workforce reduction, which may affect morale and productivity.
• Customers may benefit from the company's continued investment in research and development and new product offerings.
• Suppliers may be affected by changes in the company's production and supply chain strategies.
• Creditors may be monitoring the company's financial performance and compliance with debt covenants.

Next Steps

• The company plans to continue to invest in research and development to enhance existing products and develop new products.
• The company intends to improve results of operations in an effort to achieve cash flow positivity.
• The company will continue to monitor and manage its financial covenants under the Midcap Trust Term Loan.

Key Dates

Keywords

spatial biology, phenotyping, instruments, reagents, revenue, net loss, workforce reduction, cost savings, installed base, clinical research, diagnostics